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This study aimed to evaluate the clinical and economic implications of integrating human papilloma virus (HPV) load testing into the
follow-up and management protocol of women postconisation for high-grade cervical intraepithelial neoplasia (CIN2–3). We
evaluated 130 suitable women: 63 were screened biannually by Pap smears (‘conventional approach’) and 67 also had HPV-load
testing (‘HPV approach’). More stringent criteria for undergoing colposcopy or reconisation were observed by the former group
compared to the latter. Both approaches were analysed for cost effectiveness. There were 33 out of 67 (49.2%) colposcopic referrals
and 24 out of 67 (35.8%) reconisation/hysterectomies with the ‘conventional approach’ compared to 9 out of 63 (14.2%) and 7 out
of 63 (11.1%) with the ‘HPV approach’. Cervical intraepithelial neoplasia 2–3 residual disease was detected in 7 out of 67 (10.5%)
and 7 out of 63 (11.1%) women. The ‘conventional approach’ had more negative colposcopic biopsies and more negative
reconisation/hysterectomy histologies than the ‘HPV approach’. The respective cost per detection of one case of residual disease was
US$3573 and US$3485. The ‘HPV approach’ required fewer colposcopic and reconisation procedures to detect one case of residual
CIN2–3. Its higher positive predictive value than that of cytology provided a significant decrease in false positive rates and a reduction
of US$88 per detected case.
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The diagnosis of high-grade cervical intraepithelial neoplasia
(CIN2–3) bears a significant risk of developing invasive carcinoma
if not treated (Pinto and Crum, 2000). The recurrence rate after
cone biopsy in such cases is estimated to be between 5 and 30%
(Bjerre et al, 1976; Kolstad and Klem, 1976; Larsson et al, 1983).
Early diagnosis of residual or recurrent cervical disease is one of
the main objectives in the follow-up of women following cone
biopsy due to CIN2–3. Three diagnostic modalities, cervical
cytology, colposcopy-directed biopsy and human papilloma virus
status, have been previously suggested for the follow-up of such
women. Currently, cervical cytology is the main screening
modality being used for triaging them for further evaluation and
treatment (Montz, 2000).
Cervical cytology has significant inherent potential drawbacks.
The first and most significant of them is a false negative result
which precludes women with undiagnosed lesions from being
referred for a proper evaluation, with the consequent obvious risk
of developing invasive cervical disease. In addition, cervical
cytology is associated with a substantial false positive rate that
may create an overload in the work schedule of the limited
available colposcopic units, causing a delay in the referral of true
positive cases for colposcopic evaluation and leading to over-
treatment, which is inevitably accompanied by anxiety, morbidity
and monetary costs (Beutner et al, 1998).
Colposcopy-directed biopsy is considered as the ‘gold-standard’
diagnostic modality for detecting residual disease after therapeutic
conisation. Most recent reports show that the majority of low-
grade cervical intraepithelial neoplasia (CIN1 lesions) will
spontaneously remit (Baron and Richart, 1970; Noumoff, 1987;
Hoskins et al, 1992) and that the risk of progression to CIN3 or
invasive disease is minor. Accordingly, the main objective is to
detect the CIN2–3 lesion, which has a significant risk to progress
to invasive disease. Thus, identifying high-grade lesions in low–
grade cytology smears becomes a matter of considerable
importance.
Human papilloma virus (HPV), which is the most common viral
sexually transmitted disease in the United States (Hoskins et al,
1992), has since 1977 been considered an aetiologic agent for
cervical cancer (Meisels et al, 1977) and is currently unequivocally
linked with the development of precancerous lesions of the cervix.
High-risk HPV subtypes are associated with the presence of high-
grade squamous intraepithelial lesion (HSIL) or CIN2–3 (Baron
and Richart, 1970). Adding HPV testing to cytology as part of the
follow-up protocol of this high-risk group of patients after they
had undergone therapeutic cone biopsy due to CIN2–3 may have
good predictive ability. Indeed, ter Harmsel et al (1999) concluded
that persistent infection with HPV 16 is associated with a higher
risk of developing CIN, which is often high grade.
Previous studies on the relation between the quantitative level of
HPV DNA and histologic severity of cervical lesions have yielded
controversial results. Several studies using the semiquantitative
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ypolymerase chain reaction analysis (PCR) have shown a correla-
tion between HSIL and a large amount of HPV-16 DNA in cervical
samples and a small amount in samples of a low-grade squamous
intraepithelial lesion (LSIL) (Cuzick et al, 1992, 1994; Bavin et al,
1993). In contrast, two other studies using a Hybrid Capture assay
revealed smaller amounts of viral DNA in the cervical samples of
women with HSIL compared with LSIL (Farthing et al, 1994; Sun
et al, 1995).
We performed this prospective cohort study in order to test our
hypothesis that adding assessment of the HPV load of high-risk
types as a triaging tool would enable the reduction of the number
of colposcopic and reconisation procedures for the detection of
one case of residual CIN2–3. To this end, we compared the clinical
and economic implications of two different approaches to the
follow-up and management of women postconisation due to
CIN2–3 lesions, namely the ‘conventional (cytology) approach’ vs
the ‘HPV (load) approach’.
MATERIALS AND METHODS
This prospective study was carried out on a cohort of 139
consecutive patients with CIN2–3 lesions who underwent cone
biopsies at the Cervical Pathology Unit of the Tel Aviv Medical
Center between January 1994 and December 1998. A Pap smear
had been used as the screening method for the first 72 patients
(Group 1, the ‘conventional approach’) until October 1996, when
HPV load assessment was added to the screening protocol of the
remaining 67 patients (Group 2, the ‘HPV approach’). The mean
follow-up was 53 months (range 25–77). Five of the 72 patients in
Group 1 were excluded: three failed to attend all the follow-up
visits and the other two were lost to follow-up. Four of the 67
patients in Group 2 were excluded: the HPV test results were
incomplete in two and the other two were lost to follow-up.
The mean age was 38.8 years (range 17–54) for the Group 1
patients and 37.4 years (range 16–51) for the Group 2 patients.
The following characteristics were similar between the two study
groups: contraception use, education level, marital status and
positive surgical margins (the latter values were 10.4 and 11.0% for
Groups 1 and 2, respectively).
The follow-up protocols as well as the indications for colpo-
scopic and reconisation procedures are summarised in Table 1.
The follow-up visits took place at 6-month intervals for up to 2
years and annually thereafter. For Group 1, the indication for
colposcopy was two consecutive abnormal Pap smears. The
indication for reconisation was a CIN result of any degree on
colposcopic biopsy. For Group 2, the indications for colposcopy
were HSIL on cytology or a high viral load on an HPV test. The
indication for reconisation in this group was restricted to CIN2–3
on colposcopic biopsy. Women with low-grade lesions on cytology
(atypical squamous cell of undetermined significance (ASCUS) or
LSIL) and a low-load HPV, which did not indicate colposcopy,
were followed by serial cytologies (at intervals of 6 months).
Likewise, women with low-grade lesions on colposcopy (CIN1)
were referred back for follow-up by serial cytology.
We used the type 1 Hybrid Capture Test System (Digene
Corporation, Silver Spring, MD, USA). Samples for the presence of
a cocktail limited to the following high-risk HPV types (16, 18, 31,
33, 35, 45, 51, 52, 56) were collected from the external cervical os
and the exocervix by a special brush applicator and transferred to
the lab in a container with transfer media provided in a specific kit
by Digene Corp. In the type 1 Hybrid Capture assay, light is
emitted during the cleavage of the tested substrate. The intensity of
the emitted light is proportional to the amount of DNA present in
the examined specimen. A relative light unit (RLU) measurement
greater than or equal to the cutoff value indicates the presence of
HPV DNA, whereas an RLU measurement less than the cutoff
value indicates the absence of an HPV DNA sequence. Based on the
above principles, the following scale of HPV load was used: an RLU
o0.3 units¼a negative HPV DNA test, an RLU between 0.4 and 3
units¼a borderline test, an RLU between 4 and 9 units¼a low
HPV DNA load test and an RLU 410¼a high-load HPV DNA
test.
A standard cone biopsy was performed by loop excision of the
transformation zone (LETZ) followed by laser vaporisation of the
crater base and side walls, as previously described (Bar-Am et al,
2000). The specimen sizes usually range between 1.8cm in depth
and 1.5cm in width.
The health insurer of each woman funded the cost of treatment
and follow-up. The prices for cost per case of detected residual
CIN2–3 and the cost-effectiveness analysis were based on the
official prices issued by the country’s national healthcare
providers: a visit to the doctor¼$30, each Pap smear¼$18,
colposcopy and cervical biopsy¼$80, histologic analysis for
colposcopy¼$50 ($70 for cone histology), Hybrid Capture
test¼$40 ($70 including doctor’s visit) and cone biopsy¼$80.
These are the government estimates for the cost of the procedures
that were issued in order to define tariffs in the public health
system (in US dollars according to the rate of exchange for local
currency of May 2001). The cost per detected case was calculated
accordingly.
Statistics
Significant differences in proportions were assessed by Fisher’s
exact test. All the statistical analyses were performed using SPSS
for Windows version 8.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
In all, 67 women who were treated by the ‘conventional approach’
(Group 1) and 63 women who were treated by the ‘HPV approach’
(Group 2) completed the follow-up period according to the study
protocol (Table 1). Table 2 presents their clinical outcome data.
The two groups were equal in terms of the number of LSIL and
HSIL cases in each and the overall CIN2–3 residual disease
detected by reconisation/hysterectomy.
There were significantly more colposcopic referrals (49.3 vs
14.2%, Po0.001) and reconisation referrals (35.8 vs 11.1%,
Table 1 Triaging modalities and indications for colposcopy and reconisation for the two study groups
Procedures Conventional approach (Group 1) HPV approach (Group 2)
Triaging modality Pap smear every 6 months Pap smear and HPV load every 6
months
Indications for colposcopy Two consecutive abnormal Pap smears HSIL in Pap smear or high viral HPV
load
Indications for reconisation Any CIN CIN2–3
HPV¼human papilloma virus; HSIL¼high-grade squamous intraepithelial lesion; CIN1, 2–3¼cervical intraepithelial
neoplasia 1, 2–3.
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was a trend of more negative colposcopic biopsies (27.2 vs 11.1%)
as well as negative reconisation/hysterectomy histologies (37.5 vs
0%) in Group 1 compared to Group 2, respectively.
Importantly, there were a total of 22 cases of LSIL or low-load
HPV in Group 2 that did not indicate colposcopy, as well as one
case of CIN1 on colposcopy. The total number of detected cases of
CIN2–3 residual disease was similar between the two groups, that
is, 7 (10.5%) and 7 (11.1%) for Groups 1 and 2, respectively.
Table 3 summarises the precision of prediction of any type of
CIN by abnormal cytology or HPV load. The superiority of HPV
load in the prediction of any CIN over abnormal cytology can be
clearly seen. The positive predictive values (PPV) of LSIL to any
CIN were relatively low (4.2–33.3%), whereas the PPV of HSIL to
any CIN residual disease or, more importantly, to CIN2–3 was 77.7
and 66.6%, respectively. The PPV of high-load HPV for CIN2–3
was 100%.
The cost of detecting one case of a CIN2–3 lesion according to
the ‘conventional approach’ (Group 1) was US$2964. If we had
applied the ‘conventional approach’ to the whole study group, the
cost-effectiveness ratio would be US$3573. The cost of detecting
one case of a CIN2–3 lesion according to the ‘HPV approach’ was
US$3485. Thus, adding an HPV load assessment to the standard
Pap protocol for this selected group of women would yield a
decrease in cost of US$88 per detection of one case of a residual
CIN2–3 lesion.
DISCUSSION
In spite of the relatively high rate of clearance (95% (Reich et al,
2002)), patients after conisation due to CIN2–3 are at a higher risk
of developing residual or recurrent disease than controls. Their
regular follow-up protocol after conisation includes continued
cytological and colposcopic examination as well as reconisation in
cases of suspected residual/recurrent lesions (Milojkovic, 2002).
The optimal management of low-grade cytologies or histologies,
such as ASCUS, LSIL or CIN1, in such cases remains undetermined
(Livasy et al, 1999; Nagai et al, 2000; Reich et al, 2001).
The main objective of the present prospective cohort study was
to analyse the clinical and economic contribution of adding an
HPV-load test to the standard cytological follow-up following
therapeutic conisation due to CIN2–3. Indications for advanced
diagnostic procedures were allowed to be restricted whenever the
HPV load was assessed (the ‘HPV approach’), but they were to be
expanded whenever only cytology had been used for triaging
subjects (the ‘conventional approach’).
A comparison between the two study groups shows that HPV-
load evaluation identifies the presence of CIN2–3 at a detection
rate equal to the standard cytological approach, but with
significantly fewer colposcopies and reconisation procedures.
The main contribution of an HPV-load evaluation is its ability to
identify normal or low-grade lesions that might progress to high-
grade lesions. Three such patients from Group 2 with normal
cytologic results were further evaluated only due to the discovery
of a high HPV load and they were eventually proved to be CIN2–3.
Accordingly, the PPV of a high-load HPV test was maximal (i.e.,
100%) according to these findings.
When an HPV-load evaluation is unavailable for the follow-up
of such a high-risk group and initial triaging is performed by
repeated cytologies, however, one must seriously consider further
and complete histological evaluation of all ASCUS, LSIL and CIN1
results. The case of LSIL that was additionally evaluated by
colposcopy and subsequently reclassified as CIN2–3 in Group 1
supports this contention. Such a policy, however, results in a high
rate of colposcopic and reconisation referrals and, consequently, a
Table 2 Comparison between the two approaches tested
Characteristics or outcomes
Conventional approach
(Group 1) n¼67
HPV approach
(Group 2) n¼63 P-value
*
Cytology results
(%)
LSIL 24 (35.8) 21 (33.3) 0.85
HSIL 9 (13.5) 6 (9.5) 0.58
Procedures performed (%) Colposcopies 33 (49.3) 9 (14.2) o0.001
Reconisations/ hysterectomies 24 (35.8) 7 (11.1) 0.001
Colposcopic histology (%) Negative 9 (27.2) 1 (11.1) 0.41
CIN1 17 (51.5) 1 (11.1) 0.03
CIN2–3 7 (21.2) 7 (77.7) 0.003
Reconisation/hysterectomy histology (%) Negative 9 (37.5) 0 (0) 0.07
CIN1 8 (33.3) 0 (0) 0.09
CIN2–3 7 (29.2) 7 (100) 0.001
Overall CIN2–3 (%) 7/67 (10.5) 7/63 (11.1) 1.0
*Significance by Fisher’s exact test. HPV¼human papilloma virus; CIN1, 2–3¼cervical intraepithelial neoplasia 1, 2–3; LSIL¼low-grade squamous intraepithelial lesion;
HSIL¼high-grade squamous intraepithelial lesion.
Table 3 Positive predictive value and false positive rates of LSIL, HSIL and high-load HPV to any CIN, to
CIN1 and to CIN2–3
Test
PPV to any CIN
(%)
PPV to CIN1
(%)
PPV to CIN2–3
(%)
False positive rate
(%)
LSIL 33.3 29.1 4.2 66.6
HSIL 77.7 11.1 66.6 22.2
HL-HPV 100 0 100 0
PPV¼positive predictive value; CIN1, 2–3¼cervical intraepithelial neoplasia grade 1, 2-3; HL¼high-load HPV DNA;
LSIL¼low-grade squamous intraepithelial lesion; HSIL¼high-grade squamous intraepithelial lesion.
Benefits of HPV testing for women postcone for CIN2–3
B Almog et al
111
British Journal of Cancer (2003) 89(1), 109–112 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yhigh number of low-grade colposcopic and reconisation histologic
results.
Previous studies on the relation between the HPV load and the
histologic grade of cervical lesions have yielded controversial
results. Several investigations in which a semiquantitative PCR was
used showed a significant correlation between cytological grade
and the amount of HPV-16 DNA in cervical samples (Cuzick et al,
1992, 1994; Bavin et al, 1993). In contrast, two other studies using
Hybrid Capture assays revealed smaller amounts of viral DNA in
cervical samples of women with HSIL compared to those with LSIL
(Farthing et al, 1994; Sun et al, 1995). Sun et al (2001) recently
revealed that the effect of HPV infection on SIL development is
dominated by the viral load, thus highlighting a potential
application of viral load testing in predicting the advancement of
cervical intraepithelial lesions. Ylitalo et al (2000) reported that
CIN3 is associated with HPV-16-positive women who have
consistently high viral loads, and Sherman et al (2002) concluded
that for women with ASCUS, HPV-load testing is highly sensitive
for detecting CIN3 and cancer with dramatically fewer referrals for
colposcopy.
We have shown a reduced cost per detection of one case of
residual CIN2–3 lesion if HPV-load assessment were to be
included in addition to the standard Pap smear. Several authors
have independently reported that inclusion of HPV assessment in
screening for cervical cancer may be more clinically effective than
Pap tests alone at higher but still ‘reasonable costs’ (Goldie et al,
2001; Kim et al, 2002; Mandelblatt et al, 2002). These costs were
calculated for quality-of-life measures or years of life saved.
Although we did not perform a complete cost-utility analysis, we
believe that the distinct significance of the present results applies
to the evaluation of different triaging protocols for women at high
risk for CIN2–3, rather than as a primary screening protocol. To
conclude, we regard the ‘HPV approach’ as the more reasonable
choice for such a selective and high-risk group, even had our
results shown a small incremental cost.
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